MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.

    N. Ayo (Barakaldo, Spain)

    Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…
  • 2022 International Congress

    Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, M. Scelsi, L. Essioux, A. Monnet, B. van Lier, H. Svoboda, T. Kustermann, W. Zago, T. Nikolcheva, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

    Objective: To determine whether the positive effects of prasinezumab on motor progression measured by Roche PD Mobile Application (PASADENA study Part 1; 0-52 weeks; NCT03100149)…
  • 2022 International Congress

    Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…
  • 2022 International Congress

    A fully immersive virtual reality environment to study gait modulation in Parkinson’s disease

    I. Hanafi, P. Kullmann, IU. Isaias, C. Palmisano (Würzburg, Germany)

    Objective: To investigate the safety and efficacy of a fully immersive virtual reality (VR) paradigm to study gait modulation in subjects with Parkinson’s disease (PD).…
  • 2022 International Congress

    Prediction of early-stage Parkinson’s disease using connectivity and morphometry of the striatum

    D. Henadeerage Don, E. Alushaj, N. Handfield-Jones4, A. Khan, P. Macdonald (London, Canada)

    Objective: To parcellate the striatum into sub-regions and extract connectivity and surface morphometry features that can distinguish early patients with PD using machine learning. Background:…
  • 2022 International Congress

    Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia

    E. Pipan, N. Zupančič Križnar, L. Ocepek, R. Rajnar, M. Kramberger, M. Menih, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

    Objective: To study the initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) in routine clinical practice at two University Medical Centers in Slovenia. Background: The…
  • 2022 International Congress

    Can abdominal internal oblique muscle be a possible target for ultrasound-guided Botulinum toxin injection in patients with Parkinson’s Disease affected by axials problems? An ultrasound study of our case series.

    F. Marenco, P. Arcuri, M. Meloni, M. Ramella, A. Castagna (Milan, Italy)

    Objective: to demostrate the abdominal internal oblique muscle hypertrophy with ultrasound in patients with Parkinson’s Disease (PD) affected by axial problems, as a possible target…
  • 2022 International Congress

    Gait declines faster over time in people with Parkinson’s disease converting to a freezing of gait phenotype

    T. Virmani, A. Glover, L. Pillai (Little Rock, USA)

    Objective: To monitor gait progression in people with Parkinson’s disease (PwPD) who convert from a non-freezing (noFOG) to a freezing of gait (FOG) phenotype. Background:…
  • 2022 International Congress

    Neuroprotective trial design methodology for Parkinson’s: a scoping review

    E. King, M-L. Zeissler, P. Sharpe, T. Boey, F. O'Brian, D. Chapman, G. Rafaloff, K. Raphael, H. Venkatesh, C. Carroll (Plymouth, United Kingdom)

    Objective: To further understanding of the diversity and impact of trial design choices in trials of disease modifying therapy (DMT) in Parkinson’s disease (PD). Background:…
  • 2022 International Congress

    Insights from skin biopsies: α-synuclein real-time quaking-induced conversion (RT-QuIC) in patients with Parkinson’s disease and multiple system atrophy

    C. Panzer, J. Volkmann, C. Sommer, K. Doppler, A. Kuzkina (Würzburg, Germany)

    Objective: To characterize skin alpha-synuclein (α-syn) pathology in synucleinopathies as a potential tool for differential diagnosis. Background: Differential diagnosis of PD and MSA represents a…
  • « Previous Page
  • 1
  • …
  • 322
  • 323
  • 324
  • 325
  • 326
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley